New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox &amp; Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. (&#34;ARS&#34; or the &#34;Company&#34;)

<p>New York, New York--(Newsfile Corp. - August 17, 2026) - <a href="https://api.newsfilecorp.com/redirect/OAJAGi3QJb">Kaplan Fox &#38; Kilsheimer LLP</a> announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SPRY">SPRY</a>) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/PqGqQUqan8">CLICK HERE TO JOIN THE CASE</a></p><p><b>If you are an investor in ARS and have suffered losses, you may </b><a href="https://api.newsfilecorp.com/redirect/wEgExcrE58"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p><b>DEADLINE REMINDER: </b>If you are a member of the proposed Class, you may move the court <u><b>no later than October 5, 2026</b></u> to serve as a lead plaintiff for the purported class.  If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.</p><p>The complaint alleges on June 24, 2026, after the market closed, ARS published a press release providing an update on payer access for neffy, which stated, in pertinent part, "[d]espite certain payer discussions ongoing until mid-June, based on recent feedback, no new commercial formulary additions or coverage decisions have been issued for neffy in the July 1, 2026 cycle." Following this news, the price of ARS stock fell $2.52 per share, or 23.9%, to close at $8.02 per share on June 25, 2026. </p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America&#8212;</i>the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act<i>&#8212;</i>$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this Notice, your rights, or your interests, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/vEwE2cD1AO">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/JkVkzIAVZb">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/GzXzDuyBLA">https://www.kaplanfox.com/case/ars-pharmaceuticals-inc-investor-alert-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/309908_cbd60a7de426c9f5_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/Q2Q2mI7Nxn">https://www.newsfilecorp.com/release/309908</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/309908/197" alt="" /></p>

SPRY

Kaplan Fox Urges Investors of ARS Pharmaceuticals Inc. (SPRY) with Significant Losses to Seek a Leadership Role Before October 5, 2026

Class action against ARS Pharmaceuticals signals SPRY legal exposure

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox &amp;amp; Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. (&amp;#34;ARS&amp;#34; or the &amp;#34;Company&amp;#34;)</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Kaplan Fox &amp; Kilsheimer LLP filed a securities class action against ARS Pharmaceuticals (SPRY) tied to neffy payer coverage disclosures during March 9–June 24, 2026. After ARS said no new formulary approvals for neffy in the July cycle, the stock dropped 23.9% to $8.02 on June 25. The suit highlights potential legal and governance risks that could affect SPRY through ARS dynamics.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kaplan Fox files class action against ARS (SPRY) over neffy payer issues.</li><li>Case covers March 9–June 24, 2026; market reaction cited.</li><li>ARS stock fell 23.9% to $8.02 on June 25, 2026 after update.</li><li>Lead-plaintiff deadline: October 5, 2026.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>ARS Pharmaceuticals Inc. (SPRY)</strong>: Subject of securities class action tied to neffy payer coverage; potential SPRY stock risk.</li><li><strong>Kaplan Fox &amp; Kilsheimer LLP (N/A)</strong>: Plaintiff law firm leading the case; signals seriousness but not a direct market driver.</li><li><strong>Bank of America Corp. (BAC)</strong>: Referenced in precedent of large settlements by the law firm; not a SPRY-specific driver.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. Fits as SPRY is mentioned as the ticker in a securities class action about ARS&#039;s payer disclosures; could affect investor sentiment and governance considerations.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Lawsuit may add near-term SPRY price volatility on sentiment shifts.</li><li>News ties to ARS neffy payer coverage and formulary disclosures.</li><li>Lead plaintiff deadline October 5, 2026 sets a catalyst window.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Securities class action filed against ARS Pharmaceuticals (SPRY) by Kaplan Fox &amp; Kilsheimer LLP.</li><li>Class period from March 9, 2026 to June 24, 2026.</li><li>June 24 update: no new neffy formulary additions or coverage in July 1 cycle.</li><li>SPRY stock fell 23.9% to $8.02 on June 25, 2026.</li><li>Lead plaintiff deadline: October 5, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish near-term risk for SPRY; monitor settlement timing and disclosures.</p>
  </section>
</section>


<p>New York, New York--(Newsfile Corp. - August 17, 2026) - <a href="https://api.newsfilecorp.com/redirect/OAJAGi3QJb">Kaplan Fox &#38; Kilsheimer LLP</a> announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SPRY">SPRY</a>) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/PqGqQUqan8">CLICK HERE TO JOIN THE CASE</a></p><p><b>If you are an investor in ARS and have suffered losses, you may </b><a href="https://api.newsfilecorp.com/redirect/wEgExcrE58"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p><b>DEADLINE REMINDER: </b>If you are a member of the proposed Class, you may move the court <u><b>no later than October 5, 2026</b></u> to serve as a lead plaintiff for the purported class.  If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.</p><p>The complaint alleges on June 24, 2026, after the market closed, ARS published a press release providing an update on payer access for neffy, which stated, in pertinent part, "[d]espite certain payer discussions ongoing until mid-June, based on recent feedback, no new commercial formulary additions or coverage decisions have been issued for neffy in the July 1, 2026 cycle." Following this news, the price of ARS stock fell $2.52 per share, or 23.9%, to close at $8.02 per share on June 25, 2026. </p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America&#8212;</i>the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act<i>&#8212;</i>$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this Notice, your rights, or your interests, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/vEwE2cD1AO">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/JkVkzIAVZb">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/GzXzDuyBLA">https://www.kaplanfox.com/case/ars-pharmaceuticals-inc-investor-alert-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/309908_cbd60a7de426c9f5_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/Q2Q2mI7Nxn">https://www.newsfilecorp.com/release/309908</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/309908/197" alt="" /></p>

Kaplan Fox & Kilsheimer LLP filed a securities class action against ARS Pharmaceuticals (SPRY) tied to neffy payer coverage disclosures during March 9–June 24, 2026. After ARS said no new formulary approvals for neffy in the July cycle, the stock dropped 23.9% to $8.02 on June 25. The suit highlights potential legal and governance risks that could affect SPRY through ARS dynamics.

News insight

Kaplan Fox Urges Investors of ARS Pharmaceuticals Inc. (SPRY) with Significant Losses to Seek a Leadership Role Before October 5, 2026

AI summary

Sentiment rationale

Key facts

Legal